14045-41-1

Basic information

• Product Name: 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE
• Synonyms: 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE;5,6-DIBROMOPROTOCATECHUALDEHYDE
• CAS NO: 14045-41-1
• Molecular Formula: C₇H₄Br₂O₃
• Molecular Weight: 295.91
• Product Categories: Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 14045-41-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 334.7°C at 760 mmHg
• Flash Point: 156.2°C
• Appearance: /
• Density: 2.27g/cm³
• Vapor Pressure: 6.47E-05mmHg at 25°C
• Refractive Index: 1.732
• CAS DataBase Reference: 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE(14045-41-1)
• EPA Substance Registry System: 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE(14045-41-1)

Safety Data

• Hazardous Substances Data: 14045-41-1(Hazardous Substances Data)

Usage

General Description

2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE is a chemical compound that is commonly used as a reagent in organic synthesis. It is a yellow crystalline solid with the molecular formula C7H5Br2O3 and a molecular weight of 286.92 g/mol. 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE is known for its strong odor and is often used in the production of pharmaceuticals and other fine chemicals. It is also used as an intermediate in the synthesis of various organic compounds and serves as a valuable building block in the chemical industry. 2,3-DIBROMO-4,5-DIHYDROXYBENZALDEHYDE is considered to be toxic and should be handled with care, following proper safety protocols during use and storage.

InChI:InChI=1/C7H4Br2O3/c8-5-3(2-10)1-4(11)7(12)6(5)9/h1-2,11-12H

Upstream product

• 2973-75-3 5,6-dibromo-4-hydroxy-3-methoxybenzaldehyde 
• 121-33-5 vanillin 
• 70625-29-5 2,3-dibromo-4,5-dimethoxybenzaldehyde 
• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 70625-27-3 (+/-)-4-<2,3-Dibrom-4,5-dihydroxy-phenyl>-4-hydroxy-butan-2-on 
• 70625-29-5 2,3-dibromo-4,5-dimethoxybenzaldehyde 

Relevant articles and documents

Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer

Poly(ADP-ribose) polymerase-1 (PARP-1) is a new potential target for anticancer drug discovery. A series of bromophenol-thiosemicarbazone hybrids as PARP-1 inhibitors were designed, synthesized, and evaluated for their antitumor activities. Among them, the most promising compound, 11, showed excellent selective PARP-1 inhibitory activity (IC50 = 29.5 nM) over PARP-2 (IC50 > 1000 nM) and potent anticancer activities toward the SK-OV-3, Bel-7402 and HepG2 cancer cell lines (IC50 = 2.39, 5.45, and 4.60 μM), along with inhibition of tumor growth in an in vivo SK-OV-3 cell xenograft model. Further study demonstrated that compound 11 played an antitumor role through multiple anticancer mechanisms, including the induction of apoptosis and cell cycle arrest, cellular accumulation of DNA double-strand breaks, DNA repair alterations, inhibition of H2O2-triggered PARylation, antiproliferative effects via the production of cytotoxic reactive oxygen species, and autophagy. In addition, compound 11 displayed good pharmacokinetic characteristics and favorable safety. These observations demonstrate that compound 11 may serve as a lead compound for the discovery of new anticancer drugs.

The first synthesis of phenylpropanoid derivative bromophenols including natural products: Formation of an indene derivative compound

Synthesis of the natural bromophenols 3,4-dibromo-5-(butoxymethyl)benzene-1,2-diol, (E)-3-(2,3-dibromo-4,5-dihydroxyphenyl)-2-methylacrylaldehyde (7), 3,4-dibromo-5-(3-hydroxy-2-methylpropyl)benzene-1,2-diol and 3-(2,3-dibromo-4,5-dihydroxyphenyl)-2-pheny

Bromophenol-oxazole compound and its use in drug for treatment on diabetes mellitus type 2

The invention relates to a chemical total synthesis method of novel bromophenol-oxazole PTP1B and its use in a drug for treatment on diabetes mellitus type 2. The PTP1B inhibitor has a structural formula shown in the description. The compound improves insulin receptor sensibility through inhibiting the activity of protein tyrosine phosphatase 1B and has good treatment effects on insulin resistance-type diabetes mellitus type 2.